7MSA

GDC-9545 in complex with estrogen receptor alpha


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.24 Å
  • R-Value Free: 0.246 
  • R-Value Work: 0.194 
  • R-Value Observed: 0.197 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history


Literature

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.

Liang, J.Zbieg, J.R.Blake, R.A.Chang, J.H.Daly, S.DiPasquale, A.G.Friedman, L.S.Gelzleichter, T.Gill, M.Giltnane, J.M.Goodacre, S.Guan, J.Hartman, S.J.Ingalla, E.R.Kategaya, L.Kiefer, J.R.Kleinheinz, T.Labadie, S.S.Lai, T.Li, J.Liao, J.Liu, Z.Mody, V.McLean, N.Metcalfe, C.Nannini, M.A.Oeh, J.O'Rourke, M.G.Ortwine, D.F.Ran, Y.Ray, N.C.Roussel, F.Sambrone, A.Sampath, D.Schutt, L.K.Vinogradova, M.Wai, J.Wang, T.Wertz, I.E.White, J.R.Yeap, S.K.Young, A.Zhang, B.Zheng, X.Zhou, W.Zhong, Y.Wang, X.

(2021) J Med Chem 64: 11841-11856

  • DOI: https://doi.org/10.1021/acs.jmedchem.1c00847
  • Primary Citation of Related Structures:  
    7MSA

  • PubMed Abstract: 

    Breast cancer remains a leading cause of cancer death in women, representing a significant unmet medical need. Here, we disclose our discovery efforts culminating in a clinical candidate, 35 (GDC-9545 or giredestrant). 35 is an efficient and potent selective estrogen receptor degrader (SERD) and a full antagonist, which translates into better antiproliferation activity than known SERDs ( 1 , 6 , 7 , and 9 ) across multiple cell lines. Fine-tuning the physiochemical properties enabled once daily oral dosing of 35 in preclinical species and humans. 35 exhibits low drug-drug interaction liability and demonstrates excellent in vitro and in vivo safety profiles. At low doses, 35 induces tumor regressions either as a single agent or in combination with a CDK4/6 inhibitor in an ESR1 Y537S mutant PDX or a wild-type ERα tumor model. Currently, 35 is being evaluated in Phase III clinical trials.


  • Organizational Affiliation

    Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Estrogen receptorA [auth D],
B [auth A],
C,
D [auth B]
280Homo sapiensMutation(s): 2 
Gene Names: ESR1ESRNR3A1
UniProt & NIH Common Fund Data Resources
Find proteins for P03372 (Homo sapiens)
Explore P03372 
Go to UniProtKB:  P03372
PHAROS:  P03372
GTEx:  ENSG00000091831 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP03372
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Binding Affinity Annotations 
IDSourceBinding Affinity
ZNM BindingDB:  7MSA IC50: 0.05 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.24 Å
  • R-Value Free: 0.246 
  • R-Value Work: 0.194 
  • R-Value Observed: 0.197 
  • Space Group: P 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 53.081α = 86.43
b = 58.937β = 75.08
c = 93.551γ = 63.25
Software Package:
Software NamePurpose
REFMACrefinement
Aimlessdata scaling
PDB_EXTRACTdata extraction
XDSdata reduction
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2021-06-02
    Type: Initial release
  • Version 1.1: 2021-07-28
    Changes: Database references
  • Version 1.2: 2021-09-08
    Changes: Database references
  • Version 1.3: 2024-05-22
    Changes: Data collection